Two views of Retisert and its delivery system

Indication and Usage

RETISERT® (fluocinolone acetonide intravitreal implant) 0.59 mg is used to treat an inflammation in the back of the eye that is not caused by an infection, called chronic non-infectious uveitis.

In patients with chronic noninfectious posterior uveitis

Designed to Deliver Inflammation Control


RETISERT® (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3 to 0.4 μg/day over approximately 30 months.

How Supplied

The implant consists of a tablet encased in a silicone elastomer cup containing a release orifice and a polyvinyl alcohol membrane positioned between the tablet and the orifice. The silicone elastomer cup assembly is attached to a silicone elastomer suture tab with silicone adhesive.

Inactive Ingredients

Microcrystalline cellulose, polyvinyl alcohol, and magnesium stearate.

What's Included Inside the Package

Each implant is stored in a clear polycarbonate case within a foil pouch within a Tyvek peelable overwrap. Each packaged implant is provided in a carton that includes the package insert. Please note the external surface of the foil pouch is not sterile. However, the contents of the foil pouch are sterile.


Every unit of RETISERT® ships with a suture pack containing one 8-0 Prolene suture and one 9-0 Prolene suture.



Storage conditions:

Store in the original container at 15ºC to 25ºC (59ºF–77ºF). Protect from freezing.

Ordering Information

RETISERT® ordering:

Call 800-321-4576, then press 4
Mon-Fri / 8AM - 5PM EST

RETISERT® reimbursement assistance:

FOCUS ON ACCESS™ (866) 272-8838
Mon-Fri / 8AM - 5PM EST


Important Safety Information

  • Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg should not be used if you have an infection of the eye from viruses, bacteria, fungi or fungal diseases.

  • After receiving the Retisert® implant, you should periodically see an eye doctor for follow-up examinations of both eyes.

  • As with any surgical procedure, there is risk involved. Complications can include injury to the eye; infection; mechanical complication, movement or ejection of the implant; and wound complications following the surgery.

  • After receiving the Retisert® implant, nearly all patients will experience an immediate and temporary decrease in vision in the implanted eye that lasts for approximately 1 to 4 weeks following the surgery.

  • Based on clinical studies, within 3 years after receiving the Retisert® implant, approximately 77% of patients require medications to lower pressure in the eye, and approximately 37% of patients will require a surgical procedure to control pressure in the eye.

  • Long-term use of corticosteroids may result in an increased risk of glaucoma (high pressure in the eye).

  • Based on clinical studies, within 3 years after receiving the Retisert® implant, nearly all patients who have not already had cataracts will develop them and require surgery.

  • The most common side effects, occurring in 50-90% of patients, were cataract, increased pressure in the eye, surgery complications and eye pain. Headache was also reported in greater than 33% of patients

Please see full Prescribing Information for Retisert®

You are encouraged to report negative side effects to the FDA at or 1-800-FDA-1088.